Related references
Note: Only part of the references are listed.
Article
Clinical Neurology
Edoardo Nicolo Aiello et al.
Summary: The study compared the MMSE and MoCA in detecting cognitive deficits in post-COVID-19 patients and found that while both tools performed similarly in detecting severe cognitive sequelae, the MoCA was more sensitive in identifying sub-clinical defects and different levels of ability.
NEUROLOGICAL SCIENCES
(2022)
Article
Geriatrics & Gerontology
Edoardo Nicolo Aiello et al.
Summary: This study aimed to update region-specific norms for the Italian MoCA and provide information on sensitivity and discriminative capability at the item level. Age and education significantly predicted all MoCA measures, while substantial disagreements with previous norms classifications were detected. Certain items in the MoCA were found to lack sensitivity, particularly in the orientation and memory tasks.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
E. Guedj et al.
Summary: Several brain complications have been reported in COVID-19 patients, suggesting potential neurotropism and delayed outbreak of neuroinflammatory diseases. PET metabolism analysis showed hypometabolism in the olfactory/rectus gyrus and other brain regions, supporting the neurotropism hypothesis. Further post-viral cohort studies are needed to determine the exact relationship between these hypometabolisms and persistent disorders.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Neurosciences
Sofia Toniolo et al.
Summary: Acute delirium and neuropsychiatric symptoms are frequently reported in COVID-19 patients, possibly due to an inflammatory parainfectious process targeting the frontal lobes. While specific biomarkers of cognitive impairment in COVID-19 are lacking, further research is needed to confirm these findings.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Review
Clinical Neurology
Rania Daroische et al.
Summary: A literature review revealed that patients post COVID-19 may experience global cognitive impairment, memory difficulties, attention and executive function impairment, and verbal fluency issues. It is recommended that clinicians evaluate the need for cognitive assessment in patients with recent COVID-19 infection, and further studies are needed to investigate the condition.
FRONTIERS IN NEUROLOGY
(2021)
Letter
Medicine, General & Internal
Arne Soraas et al.
Review
Infectious Diseases
Fei Chen et al.
Summary: Dexamethasone is the first and crucial therapeutic agent that significantly reduces the risk of death in severe COVID-19 patients, alleviating SARS-CoV-2-induced complications but also posing significant adverse effects later in life. While necessary for critical patients, its potential harms cannot be overlooked, necessitating further research and clinical trials.
INFECTIOUS DISEASES AND THERAPY
(2021)
Article
Geriatrics & Gerontology
Michele Carpinelli Mazzi et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2020)
Article
Clinical Neurology
Karen Ritchie et al.
BRAIN COMMUNICATIONS
(2020)
